Investment Thesis
Alzamend Neuro is a pre-revenue pharmaceutical company in a critical financial deterioration phase, with revenue collapsing 87.7% YoY to just $1.7K while operating losses remain severe at $5.9M. The company is burning cash rapidly at $5.3M annually with minimal liquidity cushion, making near-term solvency a material concern despite holding $2.7M in cash reserves.
ALZN Strengths
- Maintains positive stockholders equity of $2.2M providing minimal balance sheet foundation
- Cash on hand of $2.7M covers approximately 5 months of current burn rate
- Low debt burden (0.00x debt-to-equity) eliminates refinancing risk
ALZN Risks
- Revenue near zero at $1.7K indicates complete absence of commercial traction or product sales
- Current ratio of 0.97x indicates immediate liquidity stress with liabilities nearly exceeding current assets
- Operating cash burn of $5.3M annually will exhaust cash reserves within months without capital injection, creating existential solvency risk
- Extreme negative margins across all profitability metrics indicate unsustainable operating model
- Pre-revenue stage with no clear path to profitability or positive cash flow
Key Metrics to Watch
- Monthly cash burn rate and runway to insolvency
- Revenue generation and clinical trial progression
- Upcoming capital raises and dilution risk
- Operating expense reduction initiatives
ALZN Financial Metrics
ALZN Profitability Ratios
ALZN Balance Sheet & Liquidity
ALZN 5-Year Financial Trend
5-Year Trend Summary: Alzamend Neuro, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-132.33 indicates the company is currently unprofitable.
ALZN Growth Metrics (YoY)
ALZN Capital Allocation
ALZN SEC Filings
Access official SEC EDGAR filings for Alzamend Neuro, Inc. (CIK: 0001677077)